A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological Malignancies

Cancer type: Hematological malignancies

Phase: I

Principal Investigator: Mau-Sørensen Morten

Country: DK

Keywords: Denmark, Rigshospitalet,selective inhibitor of nuclear expert, CRM-1, hematological malignancies

Status: Completed

Link to